HRP20172002T1 - Makrociklički inhibitori faktora xia kondenzirani sa heterociklusima - Google Patents
Makrociklički inhibitori faktora xia kondenzirani sa heterociklusima Download PDFInfo
- Publication number
- HRP20172002T1 HRP20172002T1 HRP20172002TT HRP20172002T HRP20172002T1 HR P20172002 T1 HRP20172002 T1 HR P20172002T1 HR P20172002T T HRP20172002T T HR P20172002TT HR P20172002 T HRP20172002 T HR P20172002T HR P20172002 T1 HRP20172002 T1 HR P20172002T1
- Authority
- HR
- Croatia
- Prior art keywords
- independently selected
- image
- chf
- alkyl
- pharmaceutically acceptable
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title claims 2
- 108010080805 Factor XIa Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 41
- 229910052731 fluorine Inorganic materials 0.000 claims 34
- 229910052801 chlorine Inorganic materials 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- -1 CCH3F2 Chemical group 0.000 claims 6
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 6
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 6
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 230000009424 thromboembolic effect Effects 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 1
- 206010014513 Embolism arterial Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 claims 1
- 206010063544 Renal embolism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 201000005060 thrombophlebitis Diseases 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (12)
1. Spoj sa Formulom (Ia):
[image]
ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
--- je opcionalna veza;
prsten A je nezavisno odabran od
[image]
R1 je nezavisno odabrano od H, F, OH, i C1-4 alkil;
R2 je nezavisno odabrano od H, F, i OH;
R3 je nezavisno odabrano od H, C1-4 alkil,
C1-4haloalkil, -(CH2)n-OR5, -(CH2)n-C(O)OR5, C3-6 cikloalkil po izboru supstituiran sa halogenom, i 5- do 6-očlani heteroaril koji sadrži ugljikove atome i 1-2 atoma dušika i po izboru supstituiran sa R1; pod uvjetom da je samo jedna R3 grupa prisutna na prstenu;
R4 je nezavisno odabrano od H, OH, F, OC1-4 alkil, C1-4 alkil, i CN;
R5 je nezavisno odabrano od H i C1-4 alkil;
R6 je nezavisno odabrano od H, F, Cl, Br, CN, OCH3, CH3, C(O)CH3, CHF2, CCH3F2, CF3, OCHF2, NHC(O)C1-4 alkil, C3-6 cikloalkil, i 5-očlani heterociklus supstituiran sa R9;
R7 je nezavisno odabrano od H i F;
R8 je nezavisno odabrano od H, F, Cl, i OCH3;
R9 je nezavisno odabrano od H, cijano, C1-4 alkil, haloalkil, i halogen; i
n, u svakom slučaju, je cijeli broj izabran od 1 i 2.
2. Spoj iz patentnog zahtjeva 1 koji ima Formulu (IIa):
[image]
ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
prsten A je nezavisno odabran od
[image]
R1 je nezavisno odabrano od H i C1-3 alkil;
R2 je nezavisno odabrano od H i F;
R3 je nezavisno odabrano od H, C1-3 alkil,
C1-3haloalkil, -(CH2)n-OR5, -(CH2)n-C(O)OR5, i C3-4 cikloalkil po izboru supstituiran sa halogenom;
R4 je nezavisno odabrano od H i F;
R5 je nezavisno odabrano od H i C1-4 alkil;
R6 je nezavisno odabrano od H, F, Cl, Br, CN, CF3, C(O)CH3, CHF2, CCH3F2, CF3, OCHF2,
[image]
R7 je nezavisno odabrano od H i F;
R8 je nezavisno odabrano od H, F, Cl, i OCH3;
R9 je nezavisno odabrano od H, CHF2, i CF3;
R9' je nezavisno odabrano od H, F, Cl, CN, CHF2, i CF3; i
n, u svakom slučaju, je cijeli broj izabran od 1 i 2.
3. Spoj iz patentnog zahtjeva 2, ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
R1 je nezavisno odabrano od H, CH3, i CH(CH3)2;
R2 je nezavisno odabrano od H i F;
R3 je nezavisno odabrano od H, CH3, CD3, CH2CH3, -CHF2, -CH2CHF2, -CH2CF3, -CH2CH2OH, CH2CH2OC(CH3)3, -CH2C(O)OH, ciklopropil po izboru supstituiran sa F, i ciklobutil;
R6 je nezavisno odabrano od H, F, Cl, Br, CN, CF3, C(O)CH3, CHF2, CCH3F2, CF3, OCHF2,
[image]
R7 je nezavisno odabrano od H i F;
R8 je nezavisno odabrano od H, F, Cl, i OCH3;
R9 je nezavisno odabrano od H, CHF2, i CF3; i
R9' je nezavisno odabrano od H, F, Cl, CN, CHF2, i CF3.
4. Spoj iz patentnog zahtjeva 1 koji ima Formulu (IIIa):
[image]
ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
prsten A je nezavisno odabran od
[image]
R1 je nezavisno odabrano od H, CH3, i CH(CH3)2;
R2 je nezavisno odabrano od H i F;
R3 je nezavisno odabrano od H, CH2C(=O)OH, CH2C(=O)OCH2CH3,
[image]
R4 je nezavisno odabrano od H i F;
R6 je nezavisno odabrano od H, F, Cl, Br, CN, CF3, C(O)CH3, CHF2, CCH3F2, CF3, OCHF2,
[image]
R7 je nezavisno odabrano od H i F;
R8 je nezavisno odabrano od H, F, Cl, i OCH3;
R9 je nezavisno odabrano od H, CHF2, i CF3; i
R9' je nezavisno odabrano od H, F, Cl, CN, CHF2, i CF3.
5. Spoj iz patentnog zahtjeva 1, ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
R3 je nezavisno odabrano od H, CH3, CD3, CH2CH3, -CHF2, -CH2CHF2, -CH2CF3, -CH2CH2OH, CH2CH2OC(CH3)3, -CH2C(O)OH, CH2C(=O)OH, CH2C(=O)OCH2CH3, ciklopropil po izboru supstituiran sa F, i ciklobutil,
[image]
R6 je nezavisno odabrano od H, F, Cl, Br, CN, CF3, C(O)CH3, CHF2, CCH3F2, CF3, OCHF2,
[image]
R7 je nezavisno odabrano od H i F;
R8 je Cl;
R9 je nezavisno odabrano od H, CHF2, i CF3; i
R9' je nezavisno odabrano od H, F, Cl, CN, CHF2, i CF3;
6. Spoj koji ima Formulu (IV):
[image]
ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
prsten A je nezavisno odabran od
[image]
R1 je nezavisno odabrano od H i C1-3alkil;
R2 je nezavisno odabrano od H i F;
R3 je nezavisno odabrano od H, CD3, CHF2, i CH3;
R4 je nezavisno odabrano od H i halogen;
R7 je nezavisno odabrano od H i F;
R8 je nezavisno odabrano od H, F, Cl, i OCH3; i
R9 je nezavisno odabrano od H, F, Cl, CN, i CF3.
7. Spoj koji ima Formulu (V):
[image]
ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje:
prsten A je nezavisno odabran od
[image]
R1 je nezavisno odabrano od H i C1-3alkil;
R2 je nezavisno odabrano od H i F;
R3 je nezavisno odabrano od H, CD3, CHF2, i CH3;
R4 je nezavisno odabrano od H i halogen;
R6 je nezavisno odabrano od H, F, Cl, Br, CN, CF3, C(O)CH3, CHF2, CCH3F2, CF3, OCHF2,
[image]
R7 je nezavisno odabrano od H i F;
R8 je nezavisno odabrano od H, F, Cl, i OCH3;
R9 je nezavisno odabrano od H, CHF2, i CF3; i
R9' je nezavisno odabrano od H, F, Cl, CN, CHF2, i CF3.
8. Spoj u skladu sa patentnim zahtjevom 1, 6 ili 7 odabran sa liste koja se sastoji od
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol.
9. Farmaceutska kompozicija koja sadrži jedan ili više spojeva u skladu sa bilo kojim od patentnih zahtjeva 1-8 i farmaceutski prihvatljiv nosač ili razblaživač.
10. Spoj u skladu sa bilo kojim od patentnih zahtjeva 1-8, ili stereoizomer, tautomer, ili njegova farmaceutski prihvatljiva sol ili kompozicija u skladu sa patentnim zahtjevom 9 za primjenu kao medikament.
11. Spoj u skladu sa bilo kojim od patentnih zahtjeva 1-8, ili stereoizomer, tautomer, ili njegova farmaceutski prihvatljiva sol za primjenu u liječenju i/ili profilaksi tromboembolijskog poremećaja, gdje tromboembolijski poremećaj je odabran od arterijskih kardiovaskularnih tromboembolijskih poremećaja, venskih tromboembolijskih poremećaja, i tromboembolijskih poremećaja u komorama srca ili u perifernoj cirkulaciji.
12. Spoj ili stereoizomer, tautomer, ili njegova farmaceutski prihvatljiva sol za primjenu u skladu sa patentnim zahtjevom 11, gdje tromboembolijski poremećaj je odabran od nestabilne angine, akutnog koronarnog sindroma, atrijalne fibrilacije, infarkta miokarda, prolaznog ishemijskog napada, moždanog udara, ateroskleroze, periferne okluzivne arterijske bolesti, venske tromboze, duboke venske tromboze, tromboflebitisa, arterijske embolije, koronarne arterijske tromboze, cerebralne arterijske tromboze, cerebralne embolije, bubrežne embolije, plućne embolije, i tromboze koja nastaje od medicinskih implantata, uređaja, ili procedura u kojima je krv izložena umjetnoj površini koja izaziva trombozu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933948P | 2014-01-31 | 2014-01-31 | |
| EP15705427.1A EP3099688B1 (en) | 2014-01-31 | 2015-01-30 | Macrocyclic factor xia inhibitors condensed with heterocycles |
| PCT/US2015/013647 WO2015116882A1 (en) | 2014-01-31 | 2015-01-30 | Macrocyclic factor xia inhibitors condensed with heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20172002T1 true HRP20172002T1 (hr) | 2018-02-09 |
Family
ID=52484569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20172002TT HRP20172002T1 (hr) | 2014-01-31 | 2017-12-29 | Makrociklički inhibitori faktora xia kondenzirani sa heterociklusima |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20170057961A1 (hr) |
| EP (1) | EP3099688B1 (hr) |
| JP (1) | JP6419836B2 (hr) |
| CN (1) | CN106459051B (hr) |
| AR (1) | AR099228A1 (hr) |
| BR (1) | BR112016016741B1 (hr) |
| CA (1) | CA2937738C (hr) |
| CY (1) | CY1120534T1 (hr) |
| DK (1) | DK3099688T3 (hr) |
| EA (1) | EA032650B1 (hr) |
| ES (1) | ES2655540T3 (hr) |
| HR (1) | HRP20172002T1 (hr) |
| HU (1) | HUE038060T2 (hr) |
| LT (1) | LT3099688T (hr) |
| MX (1) | MX2016009385A (hr) |
| NO (1) | NO2760821T3 (hr) |
| PL (1) | PL3099688T3 (hr) |
| PT (1) | PT3099688T (hr) |
| RS (1) | RS56785B1 (hr) |
| SI (1) | SI3099688T1 (hr) |
| TW (1) | TWI703144B (hr) |
| UY (1) | UY35972A (hr) |
| WO (1) | WO2015116882A1 (hr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2766346T (lt) | 2011-10-14 | 2017-06-12 | Bristol-Myers Squibb Company | Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| NO2760821T3 (hr) | 2014-01-31 | 2018-03-10 | ||
| WO2015116886A1 (en) | 2014-01-31 | 2015-08-06 | Bristol-Myers Squibb Company | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| ES2714283T3 (es) | 2014-09-04 | 2019-05-28 | Bristol Myers Squibb Co | Macrociclos de diamida que son inhibidores de FXIa |
| NO2721243T3 (hr) * | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| ES2762987T3 (es) | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
| CN114874222A (zh) | 2015-07-29 | 2022-08-09 | 百时美施贵宝公司 | 携带非芳族p2,基团的因子xia新大环 |
| JP6629958B2 (ja) * | 2015-07-29 | 2020-01-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤 |
| MX2018005045A (es) * | 2015-10-29 | 2018-08-01 | Merck Sharp & Dohme | Inhibidores de factor xia. |
| US10344039B2 (en) | 2015-10-29 | 2019-07-09 | Merck Sharp & Dohme Corp. | Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use |
| EP3423458A1 (en) | 2016-03-02 | 2019-01-09 | Bristol-Myers Squibb Company | Diamide macrocycles having factor xia inhibiting activity |
| EP3500556B1 (en) | 2016-08-22 | 2023-08-02 | Merck Sharp & Dohme LLC | Pyridine-1-oxide derivatives and their use as factor xia inhibitors |
| CN110248938A (zh) | 2016-11-23 | 2019-09-17 | 拜耳作物科学股份公司 | 用作农药的2-[3-(烷基磺酰基)-2h-吲唑-2-基]-3h-咪唑并[4,5-b]吡啶衍生物和类似化合物 |
| US11058115B2 (en) | 2017-01-10 | 2021-07-13 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
| US11083199B2 (en) | 2017-01-10 | 2021-08-10 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
| WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| CN110922412A (zh) * | 2018-09-20 | 2020-03-27 | 复旦大学 | 具有抗精神病作用药物化合物的不对称合成方法 |
| EP3957638A4 (en) * | 2019-04-16 | 2023-01-11 | China Resources Biopharmaceutical Company Limited | MACROCYCLIC DERIVATIVES ACTING AS FACTOR XIA INHIBITORS |
| WO2021013209A1 (zh) | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CN117603208A (zh) * | 2021-04-21 | 2024-02-27 | 上海美悦生物科技发展有限公司 | FXIa抑制剂及其药物组合物、制备方法和用途 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1525186A (fr) | 1967-03-29 | 1968-05-17 | Roussel Uclaf | Nouvelles pénicillines et procédé de préparation |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| DE4034829A1 (de) | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | Cyclopeptide |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| US5624936A (en) | 1995-03-29 | 1997-04-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1996034010A2 (en) | 1995-03-29 | 1996-10-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997036891A1 (en) | 1996-04-03 | 1997-10-09 | Merk & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
| EP1064298B1 (en) | 1998-03-19 | 2008-10-08 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
| DE69939168D1 (de) | 1998-05-26 | 2008-09-04 | Warner Lambert Co | Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| JP2002534420A (ja) | 1999-01-02 | 2002-10-15 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規なマロン酸誘導体、その調製方法、その使用およびそれを含有する医薬組成物（Ｘａ因子活性阻害） |
| EP1016663A1 (en) | 1999-01-02 | 2000-07-05 | Aventis Pharma Deutschland GmbH | Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity) |
| SK14232001A3 (sk) | 1999-04-09 | 2002-06-04 | Basf Aktiengesellschaft | Nízkomolekulové inhibítory komplementárnych proteáz |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| ES2252230T3 (es) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento. |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| WO2003011222A2 (en) | 2001-07-27 | 2003-02-13 | Merck & Co., Inc. | Thrombin inhibitors |
| US6951840B2 (en) | 2001-08-31 | 2005-10-04 | Eli Lilly And Company | Lipoglycopeptide antibiotics |
| GEP20074098B (en) | 2001-09-21 | 2007-05-10 | Bristol Myers Squibb Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| WO2003106438A1 (en) | 2002-06-18 | 2003-12-24 | The Scripps Research Institute | Synthesis of diazonamide "a" core |
| US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| US7138412B2 (en) | 2003-03-11 | 2006-11-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives useful as serine protease inhibitors |
| US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
| JP2007501844A (ja) | 2003-08-08 | 2007-02-01 | トランス テック ファーマ，インコーポレイテッド | アリール及びヘテロアリール化合物、組成物並びに使用方法 |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| WO2006017295A2 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| US7459564B2 (en) | 2005-01-13 | 2008-12-02 | Bristol-Myers Squibb Company | Substituted biaryl compounds as factor XIa inhibitors |
| US20060183771A1 (en) | 2005-02-17 | 2006-08-17 | Seiffert Dietmar A | Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors |
| US20070111947A1 (en) | 2005-10-14 | 2007-05-17 | Mcmurry Thomas J | Fibrin targeted therapeutics |
| WO2007054453A2 (en) | 2005-11-11 | 2007-05-18 | F. Hoffmann-La Roche Ag | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
| US8466295B2 (en) | 2005-12-14 | 2013-06-18 | Bristol-Myers Squibb Company | Thiophene derivatives as factor XIa inhibitors |
| EA014245B1 (ru) | 2005-12-14 | 2010-10-29 | Бристол-Маерс Сквибб Компани | Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| TW200745062A (en) | 2005-12-23 | 2007-12-16 | Bristol Myers Squibb Co | Macrocyclic factor VIIA inhibitors useful as anticoagulants |
| WO2008076805A2 (en) | 2006-12-15 | 2008-06-26 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| CN101784516B (zh) | 2007-06-13 | 2014-07-02 | 百时美施贵宝公司 | 作为凝血因子抑制剂的二肽类似物 |
| JP5537442B2 (ja) | 2008-03-13 | 2014-07-02 | ブリストル−マイヤーズ スクイブ カンパニー | 第ｘｉａ因子阻害剤としてのピリダジン誘導体 |
| US8624040B2 (en) | 2009-06-22 | 2014-01-07 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US8513433B2 (en) | 2009-07-02 | 2013-08-20 | Angion Biomedica Corp. | Small molecule inhibitors of PARP activity |
| EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| US8940720B2 (en) | 2010-02-11 | 2015-01-27 | Bristol-Myers Squibb Company | Macrocycles as factor XIa inhibitors |
| US9161924B2 (en) | 2011-07-08 | 2015-10-20 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| TW201319068A (zh) * | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| US9079929B2 (en) | 2011-10-14 | 2015-07-14 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
| LT2766346T (lt) | 2011-10-14 | 2017-06-12 | Bristol-Myers Squibb Company | Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai |
| EP2766345B1 (en) | 2011-10-14 | 2016-03-16 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| CN104136431B (zh) | 2011-12-21 | 2017-03-15 | 小野药品工业株式会社 | 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物 |
| WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| JP2015083542A (ja) | 2012-02-08 | 2015-04-30 | 大日本住友製薬株式会社 | ３位置換プロリン誘導体 |
| HUE040580T2 (hu) | 2012-05-10 | 2019-03-28 | Bayer Pharma AG | XI. véralvadási faktorhoz és/vagy XIA aktivált alakjához kötõdni képes ellenanyagok és alkalmazásuk |
| GB201209138D0 (en) | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
| TW201416362A (zh) | 2012-07-19 | 2014-05-01 | Dainippon Sumitomo Pharma Co | １－（環烷基羰基）脯胺酸衍生物 |
| CA2880898A1 (en) * | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor xia inhibitors |
| RS55975B1 (sr) | 2012-08-03 | 2017-09-29 | Bristol Myers Squibb Co | Dihidropiridon p1 kao inhibitori xia faktora |
| DK2906551T3 (en) | 2012-10-12 | 2018-05-22 | Bristol Myers Squibb Co | CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR |
| WO2014059202A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2906541B1 (en) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| EP2934538B1 (en) | 2012-12-19 | 2021-03-31 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| US9475809B2 (en) | 2013-07-23 | 2016-10-25 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives and use thereof as factor xia/plasma |
| TW201605810A (zh) | 2013-09-26 | 2016-02-16 | 拜耳製藥股份有限公司 | 經取代苯丙胺酸衍生物（二） |
| EP3049406A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen |
| EP3049403A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate |
| EP3049394A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate als faktor xia modulatoren |
| AR097755A1 (es) | 2013-09-26 | 2016-04-13 | Bayer Pharma AG | Derivados sustituidos de fenilalanina como moduladores del factor xia |
| WO2015044169A1 (de) | 2013-09-26 | 2015-04-02 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate |
| EP3049410A1 (de) | 2013-09-26 | 2016-08-03 | Bayer Pharma Aktiengesellschaft | Substituierte phenylalanin-derivate als faktor xia modulatoren |
| US20160222056A1 (en) | 2013-09-26 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Substituted phenylalanine derivatives |
| US20160229839A1 (en) | 2013-09-27 | 2016-08-11 | Merck Sharp & Dohme Corp. | Factor XIa Inhibitors |
| EP3054944B1 (en) | 2013-10-07 | 2019-12-04 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| JP6337750B2 (ja) | 2013-11-22 | 2018-06-06 | 小野薬品工業株式会社 | 化合物 |
| KR20160107322A (ko) | 2014-01-14 | 2016-09-13 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 축합 ５－옥사졸리디논 유도체 |
| NO2760821T3 (hr) | 2014-01-31 | 2018-03-10 | ||
| WO2015116886A1 (en) | 2014-01-31 | 2015-08-06 | Bristol-Myers Squibb Company | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| FI3102200T3 (fi) | 2014-02-07 | 2023-05-31 | Exithera Pharmaceuticals Inc | Terapeuttisia yhdisteitä ja koostumuksia |
| US9663527B2 (en) | 2014-02-11 | 2017-05-30 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| WO2015123093A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| WO2015123091A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| CN105829298B (zh) | 2014-02-14 | 2019-02-01 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| LT3828173T (lt) | 2014-03-07 | 2022-11-10 | Biocryst Pharmaceuticals, Inc. | Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai |
| WO2015160634A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
| KR20150136294A (ko) | 2014-05-27 | 2015-12-07 | 주식회사 레고켐 바이오사이언스 | 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물 |
| RU2016150410A (ru) | 2014-05-28 | 2018-06-28 | Мерк Шарп И Доум Корп. | Ингибиторы фактора xia |
| US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| NO2721243T3 (hr) | 2014-10-01 | 2018-10-20 | ||
| WO2016093285A1 (ja) | 2014-12-10 | 2016-06-16 | 小野薬品工業株式会社 | ジヒドロインドリジノン誘導体 |
| ES2762987T3 (es) | 2015-06-19 | 2020-05-26 | Bristol Myers Squibb Co | Macrociclos de diamida como inhibidores del factor XIA |
-
2012
- 2012-08-31 NO NO12780535A patent/NO2760821T3/no unknown
-
2015
- 2015-01-30 US US15/115,319 patent/US20170057961A1/en not_active Abandoned
- 2015-01-30 HU HUE15705427A patent/HUE038060T2/hu unknown
- 2015-01-30 PT PT157054271T patent/PT3099688T/pt unknown
- 2015-01-30 SI SI201530121T patent/SI3099688T1/sl unknown
- 2015-01-30 ES ES15705427.1T patent/ES2655540T3/es active Active
- 2015-01-30 AR ARP150100295A patent/AR099228A1/es unknown
- 2015-01-30 EP EP15705427.1A patent/EP3099688B1/en active Active
- 2015-01-30 CN CN201580017759.3A patent/CN106459051B/zh active Active
- 2015-01-30 PL PL15705427T patent/PL3099688T3/pl unknown
- 2015-01-30 TW TW104103315A patent/TWI703144B/zh active
- 2015-01-30 WO PCT/US2015/013647 patent/WO2015116882A1/en active Application Filing
- 2015-01-30 LT LTEP15705427.1T patent/LT3099688T/lt unknown
- 2015-01-30 BR BR112016016741-4A patent/BR112016016741B1/pt active IP Right Grant
- 2015-01-30 EA EA201691561A patent/EA032650B1/ru not_active IP Right Cessation
- 2015-01-30 JP JP2016549270A patent/JP6419836B2/ja active Active
- 2015-01-30 UY UY0001035972A patent/UY35972A/es active IP Right Grant
- 2015-01-30 RS RS20180033A patent/RS56785B1/sr unknown
- 2015-01-30 CA CA2937738A patent/CA2937738C/en active Active
- 2015-01-30 DK DK15705427.1T patent/DK3099688T3/en active
- 2015-01-30 MX MX2016009385A patent/MX2016009385A/es active IP Right Grant
-
2017
- 2017-08-18 US US15/680,729 patent/US20170342071A1/en not_active Abandoned
- 2017-12-29 HR HRP20172002TT patent/HRP20172002T1/hr unknown
- 2017-12-29 CY CY20171101357T patent/CY1120534T1/el unknown
-
2018
- 2018-04-06 US US15/946,837 patent/US10273236B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3099688B1 (en) | 2017-10-18 |
| US20180222907A1 (en) | 2018-08-09 |
| BR112016016741B1 (pt) | 2023-01-17 |
| US20170342071A1 (en) | 2017-11-30 |
| DK3099688T3 (en) | 2018-01-15 |
| AR099228A1 (es) | 2016-07-06 |
| TWI703144B (zh) | 2020-09-01 |
| EA032650B1 (ru) | 2019-06-28 |
| JP6419836B2 (ja) | 2018-11-07 |
| BR112016016741A2 (hr) | 2017-08-08 |
| HUE038060T2 (hu) | 2018-09-28 |
| CN106459051B (zh) | 2018-10-16 |
| EP3099688A1 (en) | 2016-12-07 |
| PL3099688T3 (pl) | 2018-03-30 |
| TW201615640A (zh) | 2016-05-01 |
| CA2937738A1 (en) | 2015-08-06 |
| UY35972A (es) | 2015-07-31 |
| SI3099688T1 (sl) | 2017-12-29 |
| US20170057961A1 (en) | 2017-03-02 |
| ES2655540T3 (es) | 2018-02-20 |
| CY1120534T1 (el) | 2019-07-10 |
| MX2016009385A (es) | 2016-09-16 |
| NO2760821T3 (hr) | 2018-03-10 |
| RS56785B1 (sr) | 2018-04-30 |
| PT3099688T (pt) | 2018-01-15 |
| LT3099688T (lt) | 2017-12-27 |
| US10273236B2 (en) | 2019-04-30 |
| WO2015116882A1 (en) | 2015-08-06 |
| CN106459051A (zh) | 2017-02-22 |
| JP2017504640A (ja) | 2017-02-09 |
| CA2937738C (en) | 2023-01-17 |
| EA201691561A1 (ru) | 2017-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20172002T1 (hr) | Makrociklički inhibitori faktora xia kondenzirani sa heterociklusima | |
| HRP20171950T1 (hr) | Pirimidinoni kao inhibitori faktora xia | |
| HRP20171122T1 (hr) | Novi makrociklusi kao inhibitori faktora xia | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| JP2017504640A5 (hr) | ||
| RU2017132433A (ru) | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение | |
| RU2017124150A (ru) | Производное дигидроиндолизинона | |
| RU2019126637A (ru) | Нейроактивные стероиды, композиции и их применения | |
| AR089134A1 (es) | Arilos y heteroarilos biciclicos inhibidores de los canales de sodio | |
| AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
| JP2018510139A5 (hr) | ||
| RU2013126041A (ru) | Пиразолопиридины и пиразолопиридины и их применение в качестве ингибиторов tyk2 | |
| RU2013132683A (ru) | Ингибиторы репликации вирусов гриппа | |
| JP2013523802A5 (hr) | ||
| JP2016530259A5 (hr) | ||
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2016515560A5 (hr) | ||
| RU2016150410A (ru) | Ингибиторы фактора xia | |
| JP2016500661A5 (hr) | ||
| AR091194A1 (es) | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| JP2010518128A5 (hr) | ||
| AR094410A1 (es) | Compuestos terapéuticos | |
| RU2013132681A (ru) | Ингибиторы репликации вирусов гриппа | |
| JP2014530838A5 (hr) |